Cytiva Partners Yoshindo to Enable Japan Biosimilar Production

Cytiva, a Danaher company and a leader in the life sciences industry, announced that it has signed a FlexFactory™ contract with Yoshindo, supporting the company’s plans to establish domestic biosimilar drug substances manufacturing capabilities for the Japanese market.

Yoshindo plans to begin supplying biosimilar products manufactured in Yoshindo’s own plant located in Toyama from 2028 onward, contributing to a more stable domestic supply of affordable biologic medicines in Japan. The project will enable Yoshindo to manufacture biosimilar drug substances using single‑use technologies, helping accelerate facility readiness while maintaining flexibility for future needs.

The facility is expected to support monoclonal antibody biosimilar drug substances manufacturing for the Japan market. This marks a significant step forward for Yoshindo’s biopharmaceutical business, for which Yoshindo has accumulated expertise over the past decade. This investment is partially supported by Japan’s Ministry of Health, Labour and Welfare (MHLW).

“This project represents an important milestone for Yoshindo as we establish an integrated in-house manufacturing system for biosimilars, from drug substances to finished drug products,” said Kenzo Shimomura, Representative Director, Yoshindo. “We aim to build flexible manufacturing capacity that can support the stable supply of biosimilar medicines for patients in Japan.”

“By working closely with Yoshindo, we are supporting the adoption of modern manufacturing approaches that can help accelerate biosimilar readiness while strengthening domestic supply resilience,” said Nick Lines, General Manager, Cytiva Japan.